Home › Companies › AMYLYX PHARMACEUTICALS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AMYLYX PHARMACEUTICALS INC.’s Form 8-K, filed June 6, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 6, 2024: 4 items on AMYLYX PHARMACEUTICALS INC.’s Form 8-K, filed June 6, 2024: 2 approved · 2 passed (calculated).
Significant dissent: 2 directors (26.1%, 25.7% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Ra Capital Management, L.P. (13F, 3.3%, as of September 30, 2026)
Explore AMYLYX PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are AMYLYX PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Joshua Cohen | 32,649,858 | -- | -- | 11,308,745 | 8,341,537 | 74% | Passed (calculated) | — |
| Elect Director: Daphne Quimi | 32,463,982 | -- | -- | 11,494,621 | 8,341,537 | 74% | Passed (calculated) | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm | 52,023,591 | 162,947 | 113,602 | -- | 0 | 99.7% | Approved | — |
| 3. Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers | 41,211,831 | 2,708,178 | 38,594 | -- | 8,341,537 | 94% | Approved | — |
Source: AMYLYX PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 6, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
162 asset managers disclosed a vote on at least one AMYLYX PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of AMYLYX PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: To elect the following persons to our board of directors, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Daphne Quimi
AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Daphne Quimi”): 32,463,982 for, 11,494,621 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 12,693,841 for, 1,758,722 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,213,630 | 0 | 0 | 109,200 | For |
| BlackRock | 2,318,983 | 0 | 0 | 0 | For |
| State Street | 1,020,563 | 0 | 0 | 1,523 | For |
| Fidelity | 907,600 | 0 | 0 | 53,800 | Mixed |
| Charles Schwab | 867,854 | 0 | 0 | 0 | For |
| T. Rowe Price | 746,800 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 633,590 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 337,210 | Withhold |
| First Trust | 0 | 0 | 0 | 311,483 | Withhold |
| JPMorgan | 293,143 | 0 | 0 | 0 | For |
| Federated Hermes | 157,412 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 138,879 | Withhold |
| TIAA | 130,661 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 130,000 | Withhold |
| Aberdeen | 0 | 0 | 0 | 118,247 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 97,308 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 89,639 | 0 | 0 | 0 | For |
| AQR | 0 | 0 | 0 | 72,858 | Withhold |
| ProShares | 0 | 0 | 0 | 70,823 | Withhold |
| Lincoln Financial | 70,047 | 0 | 0 | 0 | For |
| Equitable | 17,602 | 0 | 0 | 51,542 | Mixed |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 54,756 | Withhold |
| Dimensional | 0 | 0 | 0 | 53,981 | Withhold |
| John Hancock | 31,776 | 0 | 0 | 19,522 | Mixed |
| Voya | 49,464 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: To elect the following persons to our board of directors, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Joshua B. Cohen
AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Joshua Cohen”): 32,649,858 for, 11,308,745 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 12,814,166 for, 1,638,397 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,213,630 | 0 | 0 | 109,200 | For |
| BlackRock | 2,318,983 | 0 | 0 | 0 | For |
| State Street | 1,020,563 | 0 | 0 | 1,523 | For |
| Fidelity | 907,600 | 0 | 0 | 53,800 | Mixed |
| Charles Schwab | 867,854 | 0 | 0 | 0 | For |
| T. Rowe Price | 746,800 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 633,590 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 337,210 | Withhold |
| First Trust | 0 | 0 | 0 | 311,483 | Withhold |
| JPMorgan | 293,143 | 0 | 0 | 0 | For |
| Federated Hermes | 157,412 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 138,879 | Withhold |
| TIAA | 130,661 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 130,000 | Withhold |
| Aberdeen | 118,247 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 97,308 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 89,639 | 0 | 0 | 0 | For |
| AQR | 0 | 0 | 0 | 72,858 | Withhold |
| ProShares | 0 | 0 | 0 | 70,823 | Withhold |
| Lincoln Financial | 70,047 | 0 | 0 | 0 | For |
| Equitable | 69,144 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 54,756 | Withhold |
| Dimensional | 0 | 0 | 0 | 53,981 | Withhold |
| John Hancock | 31,776 | 0 | 0 | 19,522 | Mixed |
| Voya | 0 | 0 | 0 | 49,464 | Withhold |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 11 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executives officers.
AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“3. Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers”): 41,211,831 for, 2,708,178 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers ("NEOs").”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,322,830 | 0 | 0 | 0 | For |
| BlackRock | 2,318,983 | 0 | 0 | 0 | For |
| State Street | 1,021,956 | 130 | 0 | 0 | For |
| Fidelity | 961,400 | 0 | 0 | 0 | For |
| Charles Schwab | 867,854 | 0 | 0 | 0 | For |
| T. Rowe Price | 746,800 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 633,590 | 0 | 0 | 0 | For |
| American Century | 0 | 337,210 | 0 | 0 | Against |
| First Trust | 311,483 | 0 | 0 | 0 | For |
| JPMorgan | 293,143 | 0 | 0 | 0 | For |
| Federated Hermes | 157,412 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 138,879 | 0 | 0 | 0 | For |
| TIAA | 130,661 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 130,000 | 0 | 0 | Against |
| Aberdeen | 0 | 118,247 | 0 | 0 | Against |
| Goldman Sachs | 97,308 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 89,639 | 0 | 0 | 0 | For |
| AQR | 72,858 | 0 | 0 | 0 | For |
| ProShares | 70,823 | 0 | 0 | 0 | For |
| Lincoln Financial | 70,047 | 0 | 0 | 0 | For |
| Equitable | 69,144 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 54,756 | 0 | 0 | 0 | For |
| Dimensional | 0 | 53,981 | 0 | 0 | Against |
| John Hancock | 51,298 | 0 | 0 | 0 | For |
| Voya | 49,464 | 0 | 0 | 0 | For |
Fund voting reports, all 53 managers: 13,796,042 for, 656,521 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 1,963,444 | 0 | 0 | 0 | For |
| State Street | 1,956,432 | 130 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 1,855,886 | 0 | 0 | 0 | For |
| Two Sigma | 1,442,409 | 0 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 0 | 1,208,607 | 0 | 0 | Against |
| FARALLON CAPITAL MANAGEMENT LLC | 1,150,220 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 1,011,412 | 0 | 0 | 0 | For |
| T. Rowe Price | 990,720 | 0 | 0 | 0 | For |
| DE Shaw | 942,660 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 925,475 | 0 | 0 | 0 | For |
| Charles Schwab | 867,854 | 0 | 0 | 0 | For |
| Alpha Wave Global, LP | 840,889 | 0 | 0 | 0 | For |
| AQR | 819,468 | 0 | 0 | 0 | For |
| Citadel | 725,553 | 0 | 0 | 0 | For |
| STATE OF WISCONSIN INVESTMENT BOARD | 583,222 | 0 | 0 | 0 | For |
| Graham Capital Management, L.P. | 550,574 | 0 | 0 | 0 | For |
| Woodline Partners LP | 394,560 | 0 | 0 | 0 | For |
| JPMorgan | 352,281 | 0 | 0 | 0 | For |
| American Century | 0 | 347,706 | 0 | 0 | Against |
| SILVERARC CAPITAL MANAGEMENT, LLC | 338,045 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 320,855 | 0 | 0 | 0 | For |
| Northern Trust | 236,251 | 29 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 235,181 | 0 | 0 | 0 | For |
| AVIVA INVESTORS GLOBAL SERVICES LTD | 0 | 212,662 | 0 | 0 | Against |
| Connor, Clark & Lunn Investment Management Ltd. | 198,501 | 0 | 0 | 0 | For |
Institutional-manager reports, all 129 managers: 20,648,560 for, 2,189,011 against, 2,729 abstained, 27,102 1 year. Showing the 25 largest; every one is in the interactive database (link above).
99.8% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To vote, on a non-binding, advisory basis, on the preferred frequency of future advisory votes on the compensation of our named executives officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| First Trust | 0 | 0 | 0 | 0 | -- |
| ALPS ETF Trust | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 0 | -- |
| Aberdeen | 0 | 0 | 0 | 0 | -- |
| Goldman Sachs | 0 | 0 | 0 | 0 | -- |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 0 | -- |
| AQR | 0 | 0 | 0 | 0 | -- |
| ProShares | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| Voya | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 0 | 0 | -- |
| ETFis Series Trust I | 0 | 0 | 0 | 0 | -- |
| Allspring | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 40 managers: 12,932,726 1 year, 53,981 3 year. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| FRANKLIN ADVISERS INC | 0 | 0 | 0 | 0 | -- |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| Alyeska Investment Group, L.P. | 0 | 0 | 0 | 0 | -- |
| Rock Springs Capital Management LP | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| DE Shaw | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Alpha Wave Global, LP | 0 | 0 | 0 | 0 | -- |
| AQR | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| STATE OF WISCONSIN INVESTMENT BOARD | 0 | 0 | 0 | 0 | -- |
| Graham Capital Management, L.P. | 0 | 0 | 0 | 0 | -- |
| Woodline Partners LP | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Hudson Bay Capital Management LP | 0 | 0 | 0 | 0 | -- |
| MELLON INVESTMENTS Corp | 0 | 0 | 0 | 0 | -- |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 0 | 0 | 0 | -- |
| Sofinnova Investments, Inc. | 0 | 0 | 0 | 0 | -- |
| PANAGORA ASSET MANAGEMENT INC | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Nuveen | 0 | 0 | 0 | 0 | -- |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 74 managers: 26,532 for, 40 against, 19,437,596 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To vote, on a non-binding, advisory basis, on the preferred frequency of future advisory votes on the compensation of our named executive officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 0 | 0 | 0 | 0 | -- |
| New York Life | 0 | 0 | 0 | 0 | -- |
| GPS Funds I | 0 | 0 | 0 | 0 | -- |
| PRIMECAP Odyssey Funds | 0 | 0 | 0 | 0 | -- |
| Bridge Builder Trust | 0 | 0 | 0 | 0 | -- |
| SEI | 0 | 0 | 0 | 0 | -- |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 0 | 0 | 0 | -- |
| PACE SELECT ADVISORS TRUST | 0 | 0 | 0 | 0 | -- |
| WILSHIRE MUTUAL FUNDS INC | 0 | 0 | 0 | 0 | -- |
| Principal | 0 | 0 | 0 | 0 | -- |
| Global X | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 15 managers: 1,465,856 1 year.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 1,150,220 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| AVIVA INVESTORS GLOBAL SERVICES LTD | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 0 | 0 | 0 | -- |
| MACKENZIE FINANCIAL CORP | 0 | 0 | 0 | 0 | -- |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| Atom Investors LP | 0 | 0 | 0 | 0 | -- |
| Wellington | 0 | 0 | 0 | 0 | -- |
| Corient Private Wealth LLC | 0 | 0 | 0 | 0 | -- |
| NEW YORK STATE COMMON RETIREMENT FUND | 0 | 0 | 0 | 0 | -- |
| ROCKEFELLER FINANCIAL LLC | 0 | 0 | 0 | 0 | -- |
| Arizona State Retirement System | 0 | 0 | 0 | 0 | -- |
| PRIMECAP MANAGEMENT CO/CA/ | 0 | 0 | 0 | 0 | -- |
| SEI | 0 | 0 | 0 | 0 | -- |
| BANK OF AMERICA NA | 0 | 0 | 0 | 0 | -- |
| Man Group plc | 0 | 0 | 0 | 0 | -- |
| SCS Capital Management LLC | 0 | 0 | 0 | 0 | -- |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 0 | 0 | 0 | 0 | -- |
| Prudential/PGIM | 0 | 0 | 0 | 0 | -- |
| OREGON PUBLIC EMPLOYEES RETIREMENT FUND | 0 | 0 | 0 | 0 | -- |
| BCS Wealth Management | 0 | 0 | 2,729 | 0 | Abstain |
| XPONANCE, INC. | 0 | 0 | 0 | 0 | -- |
| Gryphon Financial Partners LLC | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 49 managers: 1,150,222 for, 2,729 abstained, 1,884,570 1 year, 39,097 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Prior year: 100.0% for (June 8, 2023 meeting) ▼ 0.3 pts
Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 52,023,591 for, 162,947 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 14,452,563 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,322,830 | 0 | 0 | 0 | For |
| BlackRock | 2,318,983 | 0 | 0 | 0 | For |
| State Street | 1,022,086 | 0 | 0 | 0 | For |
| Fidelity | 961,400 | 0 | 0 | 0 | For |
| Charles Schwab | 867,854 | 0 | 0 | 0 | For |
| T. Rowe Price | 746,800 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 633,590 | 0 | 0 | 0 | For |
| American Century | 337,210 | 0 | 0 | 0 | For |
| First Trust | 311,483 | 0 | 0 | 0 | For |
| JPMorgan | 293,143 | 0 | 0 | 0 | For |
| Federated Hermes | 157,412 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 138,879 | 0 | 0 | 0 | For |
| TIAA | 130,661 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 130,000 | 0 | 0 | 0 | For |
| Aberdeen | 118,247 | 0 | 0 | 0 | For |
| Goldman Sachs | 97,308 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 89,639 | 0 | 0 | 0 | For |
| AQR | 72,858 | 0 | 0 | 0 | For |
| ProShares | 70,823 | 0 | 0 | 0 | For |
| Lincoln Financial | 70,047 | 0 | 0 | 0 | For |
| Equitable | 69,144 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 54,756 | 0 | 0 | 0 | For |
| Dimensional | 53,981 | 0 | 0 | 0 | For |
| John Hancock | 51,298 | 0 | 0 | 0 | For |
| Voya | 49,464 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 67,975,587 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.83% |
| 2 | BlackRock | 3.41% |
| 3 | State Street | 1.50% |
| 4 | Fidelity | 1.41% |
| 5 | Charles Schwab | 1.28% |
| 6 | T. Rowe Price | 1.10% |
| 7 | FRANKLIN STRATEGIC SERIES | 0.93% |
| 8 | American Century | 0.50% |
| 9 | First Trust | 0.46% |
| 10 | JPMorgan | 0.43% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 2.89% |
| 2 | State Street | 2.88% |
| 3 | FRANKLIN ADVISERS INC | 2.73% |
| 4 | Two Sigma | 2.12% |
| 5 | Alyeska Investment Group, L.P. | 1.78% |
| 6 | FARALLON CAPITAL MANAGEMENT LLC | 1.69% |
| 7 | Rock Springs Capital Management LP | 1.49% |
| 8 | T. Rowe Price | 1.46% |
| 9 | DE Shaw | 1.39% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.36% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 11,379,207 | 16.74% | Form 13F, quarter ended March 31, 2024 |
| BlackRock | 7,140,692 | 10.50% | Form 13F, quarter ended March 31, 2024 |
| Vanguard Group | 5,273,750 | 7.76% | Form 13F, quarter ended March 31, 2024 |
| Millennium Management | 2,511,455 | 3.69% | Form 13F, quarter ended March 31, 2024 |
| Citadel Advisors | 2,262,384 | 3.33% | Form 13F, quarter ended March 31, 2024 |
| State Street | 2,060,042 | 3.03% | Form 13F, quarter ended March 31, 2024 |
| Goldman Sachs | 2,010,633 | 2.96% | Form 13F, quarter ended March 31, 2024 |
| Morgan Stanley | 1,950,301 | 2.87% | Form 13F, quarter ended March 31, 2024 |
| Franklin Templeton | 1,855,886 | 2.73% | Form 13F, quarter ended March 31, 2024 |
| Two Sigma | 1,432,865 | 2.11% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 67,975,587 shares outstanding, as reported by AMYLYX PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At AMYLYX PHARMACEUTICALS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 162 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,172 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executives officers. — AMYLYX PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AMYLYX PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AMYLYX PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
AMYLYX PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “AMYLYX PHARMACEUTICALS (AMLX) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/amylyx-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.